Mainstream

FibroGen raises China sale guidance to $210M, extends cash runway into 2028 as Phase II prostate cancer trial advances

FibroGen raises China sale guidance to $210M, extends cash runway into 2028 as Phase II prostate cancer trial advances

Post ContentfgenRead More

You might also be interested in reading Voyager Being Probed for Deceptive Crypto Marketing, FTC Says.

August 12, 2025
In Mainstream